PE20080250A1 - Proceso para la precipitacion y el aislamiento de compuestos 6,6-dimetil-3-azabiciclo [3.1.0] hexanamida mediante precipitacion controlada y formulaciones farmaceuticas que contienen dicho compuesto - Google Patents

Proceso para la precipitacion y el aislamiento de compuestos 6,6-dimetil-3-azabiciclo [3.1.0] hexanamida mediante precipitacion controlada y formulaciones farmaceuticas que contienen dicho compuesto

Info

Publication number
PE20080250A1
PE20080250A1 PE2007000535A PE2007000535A PE20080250A1 PE 20080250 A1 PE20080250 A1 PE 20080250A1 PE 2007000535 A PE2007000535 A PE 2007000535A PE 2007000535 A PE2007000535 A PE 2007000535A PE 20080250 A1 PE20080250 A1 PE 20080250A1
Authority
PE
Peru
Prior art keywords
precipitation
compound
dimethyl
isolation
compounds
Prior art date
Application number
PE2007000535A
Other languages
English (en)
Inventor
Zhihui Qiu
Wing-Kee Philip Cho
Dimitrios Zarkadas
Vincenzo Liotta
Christopher Stanley Pridgen
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of PE20080250A1 publication Critical patent/PE20080250A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Indole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

SE REFIERE A UN PROCESO DE PRECIPITACION Y AISLAMIENTO DEL COMPUESTO ( 2-CARBAMOIL-1-CICLOBUTILMETIL-2-OXOETIL)-AMIDA DE ACIDO 3-[2-(3-TERBUTIL-UREIDO)-3,3-DIMETILBUTIRIL]-6,6-DIMETIL-3-AZABICICLO[3.1.0]HEXANO-2-CARBOXILICO MEDIANTE PRECIPITACION CONTROLADA QUE COMPRENDE INTRODUCIR UNA CORRIENTE DE UNA SOLUCION DEL COMPUESTO EN UNA CORRIENTE DE ANTISOLVENTE TAL COMO HEPTANO. DICHA CORRIENTE DE ANTISOLVENTE SE PROPORCIONA EN CONDICIONES QUE PRODUCEN UN NUMERO DE REYNOLDS DE COMO MINIMO 9.000 Y LA SOLUCION SE SUMINISTRA EN CONDICIONES QUE PRODUCEN UN NUMERO DE REYNOLDS DE ALREDEDOR DE 2000. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE LA PROTEASA DEL VIRUS DE LA HEPATITIS C UTILES EN EL TRATAMIENTO DE LAS INFECCIONES POR HCV
PE2007000535A 2006-04-28 2007-05-02 Proceso para la precipitacion y el aislamiento de compuestos 6,6-dimetil-3-azabiciclo [3.1.0] hexanamida mediante precipitacion controlada y formulaciones farmaceuticas que contienen dicho compuesto PE20080250A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US79575306P 2006-04-28 2006-04-28
US79649006P 2006-05-01 2006-05-01
US79671706P 2006-05-02 2006-05-02
US87387706P 2006-12-07 2006-12-07

Publications (1)

Publication Number Publication Date
PE20080250A1 true PE20080250A1 (es) 2008-04-10

Family

ID=38565508

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007000535A PE20080250A1 (es) 2006-04-28 2007-05-02 Proceso para la precipitacion y el aislamiento de compuestos 6,6-dimetil-3-azabiciclo [3.1.0] hexanamida mediante precipitacion controlada y formulaciones farmaceuticas que contienen dicho compuesto

Country Status (8)

Country Link
US (1) US20080193518A1 (es)
EP (1) EP2012753A2 (es)
JP (1) JP5592647B2 (es)
AR (1) AR060733A1 (es)
CA (1) CA2650395A1 (es)
PE (1) PE20080250A1 (es)
SG (2) SG172690A1 (es)
WO (1) WO2007127380A2 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101918123B (zh) * 2007-12-07 2013-12-18 X喷雾微粒公司 生产微粒的方法与装置
US8188137B2 (en) 2008-08-15 2012-05-29 Avila Therapeutics, Inc. HCV protease inhibitors and uses thereof
WO2011119262A1 (en) 2010-03-26 2011-09-29 Cerulean Pharma Inc. Methods and systems for generating nanoparticles
JP5936609B2 (ja) 2010-06-29 2016-06-22 ベラステム インコーポレイテッド キナーゼインヒビターの経口製剤
JP5923499B2 (ja) 2010-06-30 2016-05-24 ベラステム インコーポレイテッド キナーゼインヒビターの合成および使用
US8546521B2 (en) 2011-01-28 2013-10-01 Cerulean Pharma Inc. Method for fabricating nanoparticles
KR102262183B1 (ko) * 2014-04-04 2021-06-07 뉴라컴 인코포레이티드 수신 확인 방법 및 다중 사용자 전송 방법

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2608988B1 (fr) * 1986-12-31 1991-01-11 Centre Nat Rech Scient Procede de preparation de systemes colloidaux dispersibles d'une substance, sous forme de nanoparticules
US4996322A (en) * 1989-05-15 1991-02-26 Air Products And Chemicals, Inc. Separation of amides with molecular sieves
JP3282731B2 (ja) * 1990-06-15 2002-05-20 メルク エンド カムパニー インコーポレーテッド 結晶の構造および大きさを改良する結晶化方法
US5389263A (en) * 1992-05-20 1995-02-14 Phasex Corporation Gas anti-solvent recrystallization and application for the separation and subsequent processing of RDX and HMX
JPH11171700A (ja) * 1997-12-16 1999-06-29 Tanabe Seiyaku Co Ltd シスプラチン微細結晶化方法
CZ20011726A3 (cs) * 2000-05-26 2002-02-13 Pfizer Products Inc. Způsob reakční krystalizace, který umoľňuje řídit velikost částic
GB0015981D0 (en) * 2000-06-29 2000-08-23 Glaxo Group Ltd Novel process for preparing crystalline particles
US7012066B2 (en) * 2000-07-21 2006-03-14 Schering Corporation Peptides as NS3-serine protease inhibitors of hepatitis C virus
RS51031B (sr) * 2001-04-30 2010-10-31 Trommsdorff Gmbh & Co.Kg.Arzneimittel Farmaceutski aktivni estri uridina
TW586963B (en) * 2001-07-20 2004-05-11 Nektar Therapeutics Uk Ltd Method and apparatus for preparing target substance in particulate form and fluid inlet assembly for said apparatus
DE60214012T2 (de) * 2001-08-29 2006-12-21 Dow Global Technologies, Inc., Midland Verfahren zur herstellung kristalliner arzneimittelteilchen durch ausfällung
US7112340B2 (en) * 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix
DE10214031A1 (de) * 2002-03-27 2004-02-19 Pharmatech Gmbh Verfahren zur Herstellung und Anwendung von Mikro- und Nanoteilchen durch aufbauende Mikronisation
GB0300339D0 (en) * 2003-01-08 2003-02-05 Bradford Particle Design Ltd Particle formation
JP2004223451A (ja) * 2003-01-24 2004-08-12 Sankio Chemical Co Ltd 有機化合物の分離精製方法及び分離精製装置
GB0302671D0 (en) * 2003-02-06 2003-03-12 Astrazeneca Ab Pharmaceutical formulations
AU2004277419B2 (en) * 2003-09-30 2007-10-11 Brown University Research Foundation Nanoparticulate therapeutic biologically active agents
TWI371274B (en) * 2003-10-23 2012-09-01 Bristol Myers Squibb Co Process for making sterile aripiprazole of desired mean particle size
JP2005177746A (ja) * 2003-11-28 2005-07-07 Mitsubishi Chemicals Corp 有機化合物微粒子の製造方法
AR049635A1 (es) * 2004-05-06 2006-08-23 Schering Corp (1r,2s,5s)-n-((1s)-3-amino-1-(ciclobutilmetil)-2,3-dioxopropil)-3-((2s)-2-((((1,1-dimetiletil)amino)carbonil)amino)-3,3-dimetil-1-oxobutil)-6,6-dimetil-3-azabiciclo(3.1.0)hexan-2-carboxamida como inhibidor de la ns3/ns4a serina proteasa del virus de la hepatitis c
JP2008507510A (ja) * 2004-07-21 2008-03-13 フジフィルム マニュファクチャリング ユーロプ ビー．ブイ． 析出物の調製方法

Also Published As

Publication number Publication date
JP5592647B2 (ja) 2014-09-17
JP2009535345A (ja) 2009-10-01
EP2012753A2 (en) 2009-01-14
CA2650395A1 (en) 2007-11-08
SG172700A1 (en) 2011-07-28
WO2007127380A2 (en) 2007-11-08
WO2007127380A3 (en) 2008-05-22
SG172690A1 (en) 2011-07-28
US20080193518A1 (en) 2008-08-14
AR060733A1 (es) 2008-07-10

Similar Documents

Publication Publication Date Title
PE20080250A1 (es) Proceso para la precipitacion y el aislamiento de compuestos 6,6-dimetil-3-azabiciclo [3.1.0] hexanamida mediante precipitacion controlada y formulaciones farmaceuticas que contienen dicho compuesto
ATE551337T1 (de) Inhibitoren des hepatitis-c-virus
BR112013020042A2 (pt) inibidores de vírus da hepatite c
ZA200900935B (en) Hepatitis C virus inhibitors
EA201171208A1 (ru) Ингибиторы вируса гепатита с
EA201101082A1 (ru) Ингибиторы вируса гепатита с
EA201270656A1 (ru) Ингибиторы вируса гепатита с
MX2010008749A (es) Inhibidores del virus de la hepatitis c.
ECSP066570A (es) Ácidos carboxílicos macrocíclicos y acilsulfonamidas como inhibidores de replicación del hcv
EA201270622A1 (ru) Ингибиторы вируса гепатита с
PE20040836A1 (es) Derivados de nucleosidos de pirimidina como inhibidores de la replicacion de rna del virus de la hepatitis c (vhc)
SG194681A1 (en) Subsituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes useful for treating hcv infections
AR030591A1 (es) Inhibidores de proteasa peptidomimetica
HN2009000614A (es) Inhibidores nucleosidicos del hvc
PE20071131A1 (es) Nucleosidos antivirales (2r)2'-deoxi-2-metil-2-fluoro-citidina
GT201100056AA (es) Metodo para preparar compuestos macrocíclicos inhibidores de serina proteasas de hepatitis c (solicitud fraccionaria de la solicitud de patente de invencion no. a-2011-00056)
PE20080702A1 (es) PROLINAMIDAS SUSTITUIDAS COMO INHIBIDORES DEL FACTOR Xa
UY32793A (es) Compuestos inhibidores de los virus flaviviridae, composición farmacéutica que los contiene y sus usos
PE20080612A1 (es) Metodo de terapia combinada para el tratamiento de la infeccion por el virus de la hepatitis c y composiciones farmaceuticas para usar en dicha terapia
NZ592705A (en) 4-amino-4-oxobutanoyl peptide cyclic analogues, inhibitors of viral replication
PA8733401A1 (es) Compuestos de pirro[1,2-b]piridazinona
BR112013028679A2 (pt) inibidores do vírus da hepatite c
UY33473A (es) Compuestos y métodos para el tratamiento o la prevencion de infecciones por flavivirus
ATE513820T1 (de) Neue benzamidinderivate, verfahren zu deren herstellung und pharmazeutische zusammensetzung, die diese enthält
CR20110524A (es) Proceso para preparar compuestos antivirales

Legal Events

Date Code Title Description
FC Refusal